Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Patent
1994-03-08
1997-07-08
Eisenschenk, Frank C.
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
530324, 5303911, 5303888, 53038885, C07K 1646
Patent
active
056462530
ABSTRACT:
The invention provides for the production of several humanized murine antibodies specific for the antigen LK26, which is recognized by the murine antibody LK26. This antigen is expressed on all choriocarcinoma, teratocarcinoma and renal cancer cell lines whereas it is not expressed on cell lines of leukaemias, lymphomas, neuroectodermally-derived and epithelial tumour cell lines (excepting a small subset of epithelial cell lines). Furthermore, whereas renal cancer cell lines express the LK26 antigen, normal renal epithelial cells do not. Similarly, with the exception of the trophoblast, all normal adult and fetal tissues tested are negative for the LK26 phenotype. The invention also provides for numerous polynucleotide encoding humanized LK26 specific antibodies, expression vectors for producing humanized LK26 specific antibodies, and host cells for the recombinant production of the humanized antibodies. The invention also provides methods for detecting cancerous cells (in vitro and in vivo) using humanized LK26 specific antibodies. Additionally, the invention provides methods of treating cancer using LK26 specific antibodies.
REFERENCES:
patent: H1312 (1994-05-01), Coughlin et al.
patent: 4851332 (1989-07-01), Rettig et al.
patent: 5225539 (1993-07-01), Winter
Carter, P. et al. "Humanization of an anti-p185.sup.HER2 antibody for human cancer therapy". Proceedings of the National Academy of Sciences, USA, 89:4285-4289 (1992).
Gorman, S.D. et al. "Reshaping a therapeutic CD4 antibody". Proceedings of the National Academy of Sciences, USA 88:4181-4185 (1991).
Ohtomo, T. et al. "Humanization of Mouse ONS-M21 Antibody with the Aid of Hybrid Variable Regions". Molecular Immunology 32(6):407-416 (1995).
Queen, C. et al. "A humanized antibody that binds to the interleukin 2 receptor". Proceedings of the National Academy of Sciences, USA 86:10029-10033 (1989).
Riechmann, L. et al. "Reshaping human antibodies for therapy". Nature 332:323-327 (1988).
Roguska, M. et al. "Humanization of murine monoclonal antibodies through variable domain resurfacing". Proceedings of the National Academy of Sciences, USA 91:969-973 (1994).
Routledge, E. et al. "A humanized monovalent CD3 antibody which can activate homologous complement". European Journal of Immunology 21:2717-2725 (1991).
Schumacher, C.L. et al. "Use of Mouse Anti-Rabies Monoclonal Antibodies in Postexposure Treatment of Rabies". Journal of Clinical Investigation 84:971-075 (1989).
Studnick, G. et al. "Human-engineered monoclonal antibodies retain full specific binding activity by preserving non-CDR complementarity-modulating residues". Protein Engineering 7(6):805-814 (1994).
Tempest, P. et al. "Reshaping a Human Monoclonal Antibody to Inhibit Human Respiratory Syncytial Virus Infection In Vivo". Bio/Technology 9:266-271 (1991).
Verhoeyen, M. et al. "Reshaping Human Antibodies: Grafting an Antilysozyme Activity". Science 239:1534-1536 (1988).
Carr Francis Joseph
Garin-Chesa Pilar
Harris William Joseph
Old Lloyd J.
Rettig Wolfgang J.
Eisenschenk Frank C.
Memorial Sloan-Kettering Cancer Center
Scotgen Biopharmaceuticals, Inc.
LandOfFree
Recombinant human anti-LK26 antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant human anti-LK26 antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant human anti-LK26 antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2409425